The compounds of Formula I ** Formula ** or a pharmaceutically acceptable solvate, hydrate, tautomer or salt, wherein: ** Formula ** W is in which each is independently H, F, Cl, Br, 1 , OH, OCH3, OCH2CH3, SC (1-4) alkyl, SOC (1- 4) alkyl, SO2C (1-4) alkyl, -C (1-3) alkyl, -CO2R4, CONReRf, C>； = CRg or CN； wherein Rd is H, or C (1-3) alkyl； Re is H, or -C (1-3alkyl； Rf is H, or -C (1-3) alkyl； and Rg is H, -CH2OH, or -CH2CH2OH； R2 is cycloalkyl, spiro-substituted cycloalkenyl, piperidinyl, piperidinyl spiro substituted, thiophenyl, dihydrosulfonopyranyl, phenyl, phyranyl, tetrahydropyridyl or dihydropyranyl, any of which may be independently substituted with one or two of each of the following: chlorine, fluoro, hydroxy, C (1-3) alkyl and C (1 -4) alkyl； or wherein R2 is 4- (1 'hydroxye-2' yl) peperidinyl； Z is H, F, or CH3； J is CH, or N； X is ** Formula ** R2 is H or -C (1-4) alkyl, in which the two R2 can have either syn or anti stereochemistry； alternatively the two R2 in a syn ratio can be considered together to form - (CR2) n-, in which n is 2 or 3； R3 is H, C (1-4) alkyl, CH2CH2NH2, CH2CH2ORº, -COCH3, CONH2, or CO2Rº； R9 is H, C (1-4) alkyl, OR. -NA1A2, NA1SO2C (1- 4) alkyl, NA1COC (1-4) alkyl, -NHCH2CH2OCH2CH3, - N (CH2CH2OH) 2, -N (CH3) CH2CH2OCH3, -NHCH2CH2SO2CH3, -NHCH2CON (CH3) 2, or R 3 and R9 can be considered together to form oxo, -OCH2CH2O-, or -OCH2C (R °) 2CH2O-； R10 is H, -C (1-4) alkyl, -ORº, -CN, -NA1A2, -SO2CH3, -COORº, -CO2CH3, -CH2- NA1A2, -CONA1A2, CH2ORº, OC (1-4) alkylORº, - NHCH2CH2CO2Rº, - NHCH2CH2ORº, -NRºCH2CH2NA1A2, -OC (1-4) alkylNA1A2, -OCH2CO2Rº, -CH2CO2Rº, - CH3CH2SO2C (1-4) alkyl, -SO2CH2CH2NA1A2, -SOCH2CH2NA2A2DA2A2A1, CH2NA2A2A1, CH2NA2A2HY2A1, CH2CH1_A2, CH2NA2A1, CH2CH1N02, 2-CH2_1_2_2_2_2_2, C2_2_2_2_2, # 2 4H- [1,2,4] oxadiazol-5-onyl, 4H-pyrolo [2,3-b] pyrazinyl, pyridinyl, (1, 3,4] oxadiazolyl, 4H- (1,2,4] triazo1i1, tetrazolyl , pyrazolyl, [1,3,5] triazinyl, and [1,3,4] thiadiazolyl； A1 is H, -C (1-4) alkyl, or CH2CH2O
